ASBP logo

ASPIRE-LAKEWOOD HOLDINGS INC

ASBPNASDAQ
πŸ† #4763 by market capUS Equity
$7.13β–Ό $0.52 (βˆ’6.80%)
Market closed Β· at close
πŸ””
Track ASBP
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 6.8%
7dβ–Ό 16.0%
14dβ–Ό 2.1%
30dβ–Ό 19.1%
ytdβ–Ό 95.5%
1yβ–Ό 93.9%
🏦Market Cap
$10M
Small Cap
πŸ“ˆRevenue Growth (YoY)
β€”
πŸ“ŠGross Margin
-25.1%
Thin
πŸ’΅FCF Margin
β€”
βš–οΈP/S Ratio
102.4x
Expensive
Otter Score
β€”
Insufficient data

Trading Snapshot

Day Range
$7.13 – $8.12
52-Week Range
$3.31 – $205.20
Volume (shares)
24,033
Avg Volume (shares)
β€”
Shares Outstanding
1.4M
Next Earnings
β€”

Fundamentals Snapshot

Annual Revenue
$6,202
Last Q Revenue
$63,103
P/E Ratio
β€”
P/S Ratio
102.4x
EPS (TTM)
$-121.90
Dividend Yield
β€”
Dilution (1yr)
+6399.8%
ASBP logo

ASPIRE-LAKEWOOD HOLDINGS INC

ASBP
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$6K
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$19Mβ–² +1498.1% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$5Mβ–² +1756.6% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
1.5Mβ–² +6399.8% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$4Mβ–Ό βˆ’$3M YoY
StockOtter Β· stockotter.space

About ASPIRE-LAKEWOOD HOLDINGS INC

Aspire Biopharma Holdings, Inc. is an emerging pharmaceutical enterprise dedicated to pioneering and commercializing innovative sublingual drug delivery systems within the United States. Its flagship product, Instaprin, is an advanced sublingual aspirin formulation known for being soluble, pH neutral, and rapidly absorbed, making it effective for both cardiovascular emergencies and general pain management. The company is diligently developing a diverse pipeline of orally dissolving formulations. This includes a melatonin-based sleep aid, essential vitamins (D, E, and K), testosterone, and semaglutide. Furthermore, Aspire Biopharma is extending its sublingual development efforts to various therapeutic areas, such as anti-nausea treatments, antipsychotic medications, erectile dysfunction drugs, and seizure control therapies, among others. They are also exploring caffeine products, including a formulation for a single-dose sublingual pre-workout supplement. Established in 2021, the firm's main operational base is situated in Estero, Florida.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100
Analyst data unavailable.

Latest News & Updates

News unavailable.